SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

DKS is trending after a historic post-earnings collapse triggered by soft athletic footwear demand, a guidance cut, and Foot Locker integration worries, which sparked a wave of analyst price-target cuts. Retail traders are fiercely split between calling the selloff an overreaction and bottom-fishing for a bounce, while others warn of further downside or bet on a short squeezekeeping sentiment paradoxically bullish despite the rout.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is tumbling after its Q4 earnings beat was overshadowed by a weak FY2027 forecast, driven by a deliberate pivot to lower TurboTax pricing to counter AI-driven competition and customer churn. Retail sentiment on Stocktwits spiked to 'extremely bullish' despite the drop, with traders fiercely divided between seeing a buying opportunity and fearing deeper structural erosion from AI disruption.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

ASST is trending as Bitcoin's rally fuels a surge in the Bitcoin-treasury stock, with traders highlighting high short interest and the potential for a squeeze amid the CEO's recent $80M+ BTC purchase and bullish analyst commentary.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is surging on news of its exclusive global licensing deal for VEPPANU, the first FDA-approved PROTAC for ER+/HER2- breast cancer, acquired from Arvinas and Pfizer. The community is focused on the drug's blockbuster potential, heavy short interest, and the stock's perceived undervaluation despite the company being profitable with multiple commercial products.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is surging as a $1.55 billion U.S. government funding package for USA Rare Earth fuels a sector-wide rally in rare-earth and critical-minerals stocks, with retail traders on Stocktwits turning bullish and calling for a short squeeze on CRML's Greenland Tanbreez project.

Flowers Foods, Inc. engages in the production and marketing of packaged bakery foods. It offers breads, buns, rolls, snack items, bagels, English muffins, and tortillas and are sold under a variety of brand names, including Nature’s Own, Dave’s Killer Bread, Wonder, Canyon Bakehouse, Tastykake, and Mrs. Freshley’s. The company was founded by William Howard Flowers, Sr. and Joseph Hampton Flowers, Jr. in 1919 and is headquartered in Thomasville, GA.

Flowers Foods, Inc.

Flowers Foods is facing intense investor scrutiny as the stock remains pressured by volume declines, margin compression, and management's reduction of full-year guidance. While some participants are betting on a turnaround driven by the Simple Mills acquisition and cost-cutting initiatives, the community is deeply divided over the long-term sustainability of the dividend and the company's ability to navigate a challenging consumer environment.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

$CSIQ trading is highly active amid a mix of retail speculation on an imminent earnings report and legal/regulatory scrutiny, with chatter focused on a potential short squeeze and allegations of market manipulation. Broader sector momentum and catalysts like upcoming 45X credits and the subsidiary share lock-up expiry are also key talking points.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is trending as retail traders aggressively debate the imminent release of Phase 3 REGAL trial data for its lead cancer immunotherapy, with bulls anticipating a major value unlock or buyout while bears dispute the trial's design and patient population. The stock's price action remains highly volatile as the community fixates on the upcoming 

CF Acquisition Corp. VI operates as a blank check company. It focuses on the search of companies in the financial services, healthcare, real estate services, technology and software industries. The company was founded on April 17, 2020 and is headquartered in New York, NY.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is surging after securing a $13.7 billion, six-year GPU services contract for its Quake AI data center unit from an unnamed U.S. cloud customer. The community is intensely speculating on the mystery client's identity, while debating the deal's massive scale against the company's financing needs and the potential for a short squeeze given elevated short interest.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

ARCT is surging over 60% toward its best week in a year, lifted by sector-wide enthusiasm from Moderna's cancer vaccine win. Retail sentiment is increasingly bullish on ARCT's proprietary self-amplifying mRNA platform, Kostaive commercial sales, and upcoming pipeline catalysts, fueling discussions of a potential short squeeze and buyout premium, though the stock is now technically overbought with an RSI above 90.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to establish a new standard of care in cartilage repair. “Regentis is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather […]

Regentis Biomaterials (NYSE American: RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C

Regentis&#160;Biomaterials (NYSE American: RGNT)&#160;is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Milestones

Cartilage Regeneration Gains Strategic Validation The orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained additional validation when Smith+Nephew completed its acquisition of CartiHeal, a developer of cartilage repair technology, in a transaction valued at up to $330 million. The acquisition demonstrated […]

Regentis Biomaterials (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT)&#160;is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process

Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while […]

Why Did RGNT Stock Surge More Than 850% Today?

Equity

Regentis Biomaterials filed a notice to withdraw its Form F-1 registration statement, indicating that it did not wish to proceed with a proposed public offering announced last month.

Why Traders Are Piling into These Emerging Healthcare Names as New Catalysts Emerge

Biotechnology and healthcare innovation dominated investor conversations today as multiple companies delivered meaningful corporate, clinical, regulatory, and commercialization updates. From artificial intelligence-powered drug discovery platforms to neuro-oncology, regenerative medicine, wound care technologies, and autoimmune disease therapies, investors focused on companies that could potentially benefit from major industry trends while advancing important milestones of their own. $CUPR, $HYFT, $NTHI, $RGNT, $GELS, $SABS

These Emerging Innovators Are Making Big Moves

From record-setting spider silk production and regenerative medicine commercialization efforts to next-generation battery technology and AI infrastructure expansion, a diverse group of companies is demonstrating how breakthrough technologies are beginning to transition from concept to commercialization. $KBLB, $RGNT, $ADTX, $GMEX, $FAC, $STAK

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Bearish Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Current Price	$2.09
Prev Close	$2.16
Open	$2.10
Dividend Yield	0.00%
50-Day Moving Average	$2.92
Beta	3.67
Avg. Volume	158,716.23
PE Ratio	-0.78

52-Week High	$15.50
52-Week Low	$1.23
Market Capitalization	$15.17M
EPS (Annual)	-$2.64
Price to Book	2.28
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info